Advertisement

Long-term treatment with arsenite activates HER1 and HER2 through upregulating EGF, TGFα, and HSP90 in a human uroepithelial cell line

  • Peiyu Jin
  • Jieyu Liu
  • Qing Zhou
  • Sihao Li
  • Weijue Liu
  • Shuhua XiEmail author
Short Communication
  • 64 Downloads

Numerous reports have established a robust dose-response association among arsenic levels in drinking water and incidences of bladder cancer (Aballay et al. 2012; Su et al. 2011). However, the exact molecular mechanisms are not clearly explained until now. Existing evidences have indicated that the human epidermal growth factor receptors (HERs) are linked to the pathogenesis of human cancers (Kriegmair et al. 2018; Sanguedolce et al. 2019; Steuer et al. 2018; Xue et al. 2018) and have a prominent function in the advancement as well as progression of epithelial cancer (Appert-Collin et al. 2015; Esparis-Ogando et al. 2016; Yu et al. 2018). Overexpression of HER1 and HER2 has been also reported in the patients with bladder cancer (Rotterud et al. 2005; Xue et al. 2018).

Nevertheless, there are not any specific studies that focus on the mechanisms of HER1 and HER2 activation during arsenic-induced urothelial hyperplasia. Increased proliferation and migration have long been regarded as an...

Keywords

Arsenite Cell proliferation Urothelium Human Epidermal Growth Factor Receptor 

Notes

Funding information

This work was supported by the National Natural Science Foundation of China (NSFC) (81673207 and 81373023) and the Program for Liaoning Innovative Research Team in University (LNIRT) (201610159000037).

Compliance with ethical standards

Conflict of interests

The authors declare that they have no conflict of interest.

Supplementary material

10565_2019_9500_MOESM1_ESM.docx (10.2 mb)
ESM 1 (DOCX 10452 kb).

References

  1. Aballay LR, Diaz Mdel P, Francisca FM, Munoz SE. Cancer incidence and pattern of arsenic concentration in drinking water wells in Cordoba, Argentina. Int J Environ Health Res. 2012;22(3):220–31.  https://doi.org/10.1080/09603123.2011.628792.CrossRefPubMedGoogle Scholar
  2. Appert-Collin A, Hubert P, Cremel G, Bennasroune A. Role of ErbB receptors in cancer cell migration and invasion. Front Pharmacol. 2015;6:283.  https://doi.org/10.3389/fphar.2015.00283.CrossRefPubMedPubMedCentralGoogle Scholar
  3. Bertelsen V, Stang E. The mysterious ways of ErbB2/HER2 trafficking. Membranes. 2014;4(3):424–46.  https://doi.org/10.3390/membranes4030424.CrossRefPubMedPubMedCentralGoogle Scholar
  4. Cancer Genome Atlas Research N. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507(7492):315–22.  https://doi.org/10.1038/nature12965.CrossRefGoogle Scholar
  5. Das D, Xie L, Wang J, Xu X, Zhang Z, Shi J, et al. Discovery of new quinazoline derivatives as irreversible dual EGFR/HER2 inhibitors and their anticancer activities-part 1. Bioorg Med Chem Lett. 2019;29(4):591–6.  https://doi.org/10.1016/j.bmcl.2018.12.056.CrossRefPubMedGoogle Scholar
  6. De Pauw I, Lardon F, Van den Bossche J, Baysal H, Fransen E, Deschoolmeester V, et al. Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines. Mol Oncol. 2018;12(6):830–54.  https://doi.org/10.1002/1878-0261.12197.CrossRefPubMedPubMedCentralGoogle Scholar
  7. Esparis-Ogando A, Montero JC, Arribas J, Ocana A, Pandiella A. Targeting the EGF/HER ligand-receptor system in cancer. Curr Pharm Des. 2016;22(39):5887–98.CrossRefGoogle Scholar
  8. Jeong J, Kim W, Kim LK, VanHouten J, Wysolmerski JJ. HER2 signaling regulates HER2 localization and membrane retention. PLoS One. 2017;12(4):e0174849.  https://doi.org/10.1371/journal.pone.0174849.CrossRefPubMedPubMedCentralGoogle Scholar
  9. Khanjani F, Sajedi RH, Hasannia S. Rapid screening of drug candidates against EGFR/HER2 signaling pathway using fluorescence assay. Anal Bioanal Chem. 2018;410(30):7827–35.  https://doi.org/10.1007/s00216-018-1403-1.CrossRefPubMedGoogle Scholar
  10. Kriegmair MC, Wirtz RM, Worst TS, Breyer J, Ritter M, Keck B, et al. Prognostic value of molecular breast cancer subtypes based on Her2, ESR1, PGR and Ki67 mRNA-expression in muscle invasive bladder cancer. Transl Oncol. 2018;11(2):467–76.  https://doi.org/10.1016/j.tranon.2018.02.001.CrossRefPubMedPubMedCentralGoogle Scholar
  11. Liao JB, Lee HP, Fu HT, Lee HS. Assessment of EGFR and ERBB2 (HER2) in gastric and gastroesophageal carcinomas: EGFR amplification is associated with a worse prognosis in early stage and well to moderately differentiated carcinoma. Appl Immunohistochem Mol Morphol. 2018;26(6):374–82.  https://doi.org/10.1097/PAI.0000000000000437.CrossRefPubMedGoogle Scholar
  12. Najy AJ, Day KC, Day ML. The ectodomain shedding of E-cadherin by ADAM15 supports ErbB receptor activation. J Biol Chem. 2008;283(26):18393–401.  https://doi.org/10.1074/jbc.M801329200.CrossRefPubMedPubMedCentralGoogle Scholar
  13. Patil PU, D’Ambrosio J, Inge LJ, Mason RW, Rajasekaran AK. Carcinoma cells induce lumen filling and EMT in epithelial cells through soluble E-cadherin-mediated activation of EGFR. J Cell Sci. 2015;128(23):4366–79.  https://doi.org/10.1242/jcs.173518.CrossRefPubMedPubMedCentralGoogle Scholar
  14. Robichaux JP, Elamin YY, Tan Z, Carter BW, Zhang S, Liu S, et al. Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nat Med. 2018;24(5):638–46.  https://doi.org/10.1038/s41591-018-0007-9.CrossRefPubMedPubMedCentralGoogle Scholar
  15. Roskoski R Jr. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res. 2014;79:34–74.  https://doi.org/10.1016/j.phrs.2013.11.002.CrossRefPubMedGoogle Scholar
  16. Rotterud R, Nesland JM, Berner A, Fossa SD. Expression of the epidermal growth factor receptor family in normal and malignant urothelium. BJU Int. 2005;95(9):1344–50.  https://doi.org/10.1111/j.1464-410X.2005.05497.x.CrossRefPubMedGoogle Scholar
  17. Sanguedolce F, Russo D, Mancini V, Selvaggio O, Calo B, Carrieri G, et al. Prognostic and therapeutic role of HER2 expression in micropapillary carcinoma of the bladder. Mol Clin Oncol. 2019;10(2):205–13.  https://doi.org/10.3892/mco.2018.1786.CrossRefPubMedGoogle Scholar
  18. Sharma B, Kanwar SS. Phosphatidylserine: A cancer cell targeting biomarker. Semin Cancer Biol. 2018;52(Pt 1):17–25.  https://doi.org/10.1016/j.semcancer.2017.08.012.CrossRefPubMedGoogle Scholar
  19. Steuer CE, Griffith CC, Nannapaneni S, Patel MR, Liu Y, Magliocca KR, et al. A correlative analysis of PD-L1, PD-1, PD-L2, EGFR, HER2, and HER3 expression in oropharyngeal squamous cell carcinoma. Mol Cancer Ther. 2018;17(3):710–6.  https://doi.org/10.1158/1535-7163.MCT-17-0504.CrossRefPubMedPubMedCentralGoogle Scholar
  20. Su CC, Lu JL, Tsai KY, Lian IB. Reduction in arsenic intake from water has different impacts on lung cancer and bladder cancer in an arseniasis endemic area in Taiwan. Cancer Causes Control. 2011;22(1):101–8.  https://doi.org/10.1007/s10552-010-9679-2.CrossRefPubMedGoogle Scholar
  21. Wichmann H, Guttler A, Bache M, Taubert H, Rot S, Kessler J, et al. Targeting of EGFR and HER2 with therapeutic antibodies and siRNA: a comparative study in glioblastoma cells. Strahlenther Onkol. 2015;191(2):180–91.  https://doi.org/10.1007/s00066-014-0743-9.CrossRefPubMedGoogle Scholar
  22. Xue L, Maihle NJ, Yu X, Tang SC, Liu HY. Synergistic targeting HER2 and EGFR with bivalent aptamer-siRNA chimera efficiently inhibits HER2-positive tumor growth. Mol Pharm. 2018;15(11):4801–13.  https://doi.org/10.1021/acs.molpharmaceut.8b00388.CrossRefPubMedPubMedCentralGoogle Scholar
  23. Yu X, Ghamande S, Liu H, Xue L, Zhao S, Tan W, et al. Targeting EGFR/HER2/HER3 with a three-in-one aptamer-siRNA chimera confers superior activity against HER2(+) breast cancer. Mol Ther Nucleic Acids. 2018;10:317–30.  https://doi.org/10.1016/j.omtn.2017.12.015.CrossRefPubMedGoogle Scholar
  24. Zhang Y, Zhang J, Liu C, Du S, Feng L, Luan X, et al. Neratinib induces ErbB2 ubiquitylation and endocytic degradation via HSP90 dissociation in breast cancer cells. Cancer Lett. 2016;382(2):176–85.  https://doi.org/10.1016/j.canlet.2016.08.026.CrossRefPubMedGoogle Scholar
  25. Zhou Q, Jin P, Liu J, Wang F, Xi S. HER2 and Src co-regulate proliferation, migration and transformation by downstream signaling pathways in arsenite-treated human uroepithelial cells. Metallomics. 2018;10(8):1141–59.  https://doi.org/10.1039/c8mt00131f.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature B.V. 2019

Authors and Affiliations

  1. 1.Department of Occupational and Environmental Health, School of Public HealthChina Medical UniversityShenyangPeople’s Republic of China

Personalised recommendations